EUVIMEDEUVIMED entdecken
Open Access

Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts

Ibrahim Fouda, Hassan Abou Khodair Mohammed, Ghada Mohammed Yousef Mohammed

Dermatology Practical & Conceptual · 30.04.2024 · 14 (2) · e2024066

DOI: 10.5826/dpc.1402a66 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 30.04.2024. Verfasst von Ibrahim Fouda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, Venereology and Andrology Department, Damietta Faculty of Medicine, Al-Azhar University, Egypt. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Warts are the most prevalent clinical manifestation of Human papillomavirus (HPV) infections, which vary in morphological pattern depending on the site of the body affected.

Objective

To evaluate the safety and efficacy of intralesional quadrivalent HPV vaccine versus candida antigen in treatment of multiple recalcitrant non-genital warts. Materials and methods: A randomized- control clinical trial included 60 cases with multiple recalcitrant warts who were randomly distributed into three groups; Group I included 20 patients who received intralesional candida antigen at a dose of 0.3 mL of 1/1000 solution, Group II included 20 patients who received intralesional quadrivalent HPV vaccine at a dose of 0.3ml and Group III included 20 patients who received intralesional injection 0.3 ml of normal saline 0.9% as a control group). Each agent was injected at the base of the largest wart every three weeks until it was completely cleared, or for a total of four sessions. Results: the highest response rate was detected in the quadrivalent HPV vaccine group (75% complete response) followed by the candida vaccine group (40% complete response and 15% partial response). Also, regarding the distant response rate, the highest response rate was detected in the quadrivalent HPV vaccine group (72.7% complete response and 27.3 % partial response) followed by the candida vaccine group (33.3 % complete response and 50 % partial response).

Conclusion

Intralesional immunotherapy appears to be effective and safe in treating multiple recalcitrant non-genital warts, with intralesional quadrivalent HPV vaccine outperforming intralesional candida antigen.

Autor:innen und Institutionen

  • Dermatology, Venereology and Andrology Department, Damietta Faculty of Medicine, Al-Azhar University, Egypt.
  • Dermatology and Venereology Department, Talkha Central Hospital, Dakahlia, Egypt.

Zitieren

APA

Fouda, I., Mohammed, H. A. K., & Mohammed, G. M. Y. (2024). Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts. Dermatology Practical & Conceptual, 14(2), e2024066. https://doi.org/10.5826/dpc.1402a66

Vancouver

Fouda I, Mohammed HAK, Mohammed GMY. Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts. Dermatology Practical & Conceptual. 2024;14(2):e2024066. doi:10.5826/dpc.1402a66

BibTeX
@article{Fouda2024,
  author = {Fouda, Ibrahim and Mohammed, Hassan Abou Khodair and Mohammed, Ghada Mohammed Yousef},
  title = {Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts},
  journal = {Dermatology Practical & Conceptual},
  year = {2024},
  volume = {14},
  number = {2},
  pages = {e2024066},
  doi = {10.5826/dpc.1402a66}
}
Kostenlos starten →